CMS Proposes National Coverage For Microvolt T-Wave Alternan Testing
This article was originally published in The Gray Sheet
Executive Summary
Cambridge Heart (HeartWave II) appears to have prevailed in its quest to obtain national coverage for Microvolt T-Wave Alternan testing to evaluate patients at risk of sudden cardiac death, despite opposition from professional societies and the three major ICD firms